Anidulafungin

Product description: Anidulafungin has a similar safety profile to caspofungin. It has proven efficacy against oesophageal candidiasis, but its main use will probably be in invasive Candida infection; it will probably also have application in treating invasive Aspergillus infection. It is a member of the class of antifungal drugs known as the echinocandins; its mechanism of action is by inhibition of (1→3)β-D-glucan synthase, which is an important component of the fungal cell wall.
Pharmacodynamics and pharmacokinetics:Anidulafungin significantly differs from other antifungals in that it undergoes chemical degradation to inactive forms at body pH and temperature. Because it does not rely on enzymatic degradation or hepatic or renal excretion, the drug is safe to use in patients with any degree of hepatic or renal impairment.
Distribution: 30-50 L
Protein binding: 84%
There is no evidence anidulafungin is metabolized by the liver. Research has shown this specific drug undergoes slow chemical hydrolysis to an open-ring peptide which lacks antifungal activity. The half life of the drug is 27 hours. Thirty percent is excreted in the feces (10% as unchanged drug). Less than 1% is excreted in the urine.
Mechanism of action:Anidulafungin inhibits glucan synthase, an enzyme important in the formation of β (1,3)-D-glucan, a major fungal cell wall component. Glucan synthase is not present in mammalian cells and therefore is an attractive target for antifungal activity.
CAS No.:166663-25-8
Molecular Formula:  C58H73N7O17